0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Intra-arterial Chemotherapy for Retinoblastoma ONLINE FIRST

Guillermo Chantada, MD, PhD1; Paula Schaiquevich, PhD2
[+] Author Affiliations
1Hemato-Oncology Service, Hospital JP Garrahan, Buenos Aires, Argentina
2National Scientific and Technical Research Council, Buenos Aires, Argentina
JAMA Ophthalmol. Published online August 11, 2016. doi:10.1001/jamaophthalmol.2016.2724
Text Size: A A A
Published online

Extract

To the Editor We read the article by Yousef et al titled “Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review.”1 From our perspective from an intra-arterial chemotherapy (ophthalmic artery chemosurgery [OAC]) program in Argentina, we believe that some issues limit the validity of their conclusions regarding the risk of metastatic relapse.

First, the population analyzed is heterogeneous, coming from centers with diverse expertise, patient number, and sociocultural discrepancies that influence outcome. In our opinion, OAC is used in some settings as a way of saving the patient’s life when, for cultural reasons, their families would not accept enucleation.2 In such cases, after failing conservative therapy, extraocular relapse would inevitably occur and these children would die despite any treatment. In other settings, like those in most Western countries, OAC is used for eye salvage. If this treatment fails, we anticipate that patients undergo enucleation without delay and, regardless of the therapy used, metastatic relapse is not typical. In the article by Yousef and colleagues, results from groups treating 3 patients per year with a metastatic rate of 25% are analyzed together with leading centers treating more than 300 patients with a relapse rate of 3.5%.1 The former was performed in a setting where the authors reported that refusal for enucleation was present3 and 3 of their 6 patients treated with OAC after failing other treatments had metastases. Hence, the different uses of OAC throughout the world with different realities imply the inclusion of patients with diverse risk of metastatic disease, which makes calculations of the risk of metastatic disease extracted from the combination of these studies questionable.

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

August 11, 2016
Carol L. Shields, MD; Jerry A. Shields, MD
1Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
JAMA Ophthalmol. Published online August 11, 2016.;():. doi:10.1001/jamaophthalmol.2016.2712.
August 11, 2016
David H. Abramson, MD; Brian P. Marr, MD; Jasmine H. Francis, MD
1Memorial Sloan-Kettering Cancer Center, New York, New York
JAMA Ophthalmol. Published online August 11, 2016.;():. doi:10.1001/jamaophthalmol.2016.2714.
August 11, 2016
Sameh E. Soliman, MD; Brenda L. Gallie, MD; Furqan Shaikh, MD
1Retinoblastoma Program, The Hospital for Sick Children, Toronto, Ontario, Canada
JAMA Ophthalmol. Published online August 11, 2016.;():. doi:10.1001/jamaophthalmol.2016.2759.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

52 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();